Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 17;13:330. doi: 10.1186/s12967-015-0683-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Tuo et al. 2015

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — Slower progression or alleviation of retinal lesions in the anti-LRP6 treated eyes as compared to the control in both models. a Representative fundoscopic images of Ccl2 ^−/− /Cx3cr1 ^−/− /rd8. Arrows indicate the yellowish deep retinal lesions. b Comparison of the average retinal lesion scores between treated and untreated eyes of 35 Ccl2 ^−/− /Cx3cr1 ^−/− /rd8 mice. Error bar mean ± SEM; *: p < 0.01. c Representative fundoscopic images of Ccl2 ^−/− /Cx3cr1 ^gfp/gfp. Arrows indicate the yellowish deep retinal lesions. In Ccl2 ^−/− /Cx3cr1 ^gfp/gfp, only 5 out of 10 treated eyes but 7 out of 10 control eyes showed lesion progression